Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Psoriasis 2Lymphoma, Follicular 2Spondylitis, Ankylosing 1Periodic Fevers Syndrome 1Motor Activity 1Melanoma 1Crohn Disease 1Colorectal Neoplasms 1Arthritis, Rheumatoid 1

Interventions

Adalimumab 6Etanercept 3Anti-Inflammatory Agents, Non-Steroidal 2tocilizumab 1secukinumab 1golimumab 1Vaccines 1Tumor Necrosis Factors 1Tai Ji 1Sulfasalazine 1Standard of Care 1Sodium Chloride 1Saline Solution 1Practice Guidelines as Topic 1Pamidronate 1Methods 1Meloxicam 1Interviews as Topic 1Infliximab 1Herpes Zoster Vaccine 1Exercise 1Etoricoxib 1Educational Status 1Early Intervention, Educational 1Celecoxib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Spondylitis, Ankylosing × secukinumab × Clear all
NCT06833112 2025-02-18

Interleukin-17 (IL-17) Inhibitor in Combination With Tumor Necrosis Factor α (TNFα )Inhibitor for the Treatment of Ankylosing Spondylitis

The Affiliated Hospital Of Guizhou Medical University

Phase 4 Not yet recruiting
10 enrolled

Spondylitis, Ankylosing

Data powered by HemOnc (CC BY 4.0) Colophon âš¡